E-LIB Suche - Ergebnisse für: Schneeweiss, S

1

RWD85 An Emulation of the KEYNOTE-189 Trial Using Electroni..:

Merola, D ; Campbell, U ; Lenis, D...
Value in Health. 27 (2024) 6 - p. S373-S374 , 2024

Link: https://doi.org/10.1016/..

2

MSR40 Predicting Treatment Effects of a New-to-Market Drug ..:

Shin, H. ; Wang, S. ; Kim, D.H....
Value in Health. 26 (2023) 6 - p. S285 , 2023

Link: https://doi.org/10.1016/..

3

MSR40 Predicting Treatment Effects of a New-to-Market Drug ..:

Shin, H. ; Wang, S. ; Kim, D.H....
Value in Health. 26 (2023) 6 - p. S285 , 2023

Link: https://doi.org/10.1016/..

4

EMPRISE: efficacité cardiovasculaire de l'empagliflozine ch..:

Patorno, E. ; Tesfaye, H. ; Wexler, D.J....
Annales d'Endocrinologie. 82 (2021) 5 - p. 266-267 , 2021

Link: https://doi.org/10.1016/..

5

Risk of connective tissue disease, morphoea and systemic va..:

Schneeweiss, M.C. ; Merola, J.F. ; Schneeweiss, S...
Journal of the European Academy of Dermatology and Venereology. 35 (2020) 1 - p. 195-202 , 2020

Link: https://doi.org/10.1111/..

6

PRO106 IMPACT of De Novo Real-World Evidence (RWE) Generati..:

Jaksa, A. ; Bradt, P. ; Patrick, A...
Value in Health. 23 (2020) - p. S708 , 2020

Link: https://doi.org/10.1016/..

7

Empagliflozin selected cardiovascular and safety outcomes i..:

Patorno, E. ; Pawar, A. ; Franklin, J.M....
Metabolism. 104 (2020) - p. 154126 , 2020

Link: https://doi.org/10.1016/..

8

Risk of connective tissue disease, morphoea and systemic va..:

Schneeweiss, M.C. ; Merola, J.F. ; Schneeweiss, S...
Journal of the European Academy of Dermatology and Venereology. 35 (2020) 1 - p. 195-202 , 2020

Link: https://doi.org/10.1111/..

9

P5003Reduced healthcare utilization in routine care initiat..:

Pawar, A ; Patorno, E ; Deruaz-Luyet, A...
European Heart Journal. 40 (2019) Supplement_1 - p. , 2019

Link: https://doi.org/10.1093/..

10

PDB126 COMPARATIVE HEALTHCARE COSTS AND MEDICATION BURDEN I..:

Pawar, A. ; Patorno, E. ; Déruaz-Luyet, A....
Value in Health. 22 (2019) - p. S161 , 2019

Link: https://doi.org/10.1016/..

11

PDB128 REDUCED HEALTHCARE UTILIZATION IN PATIENTS USING EMP..:

Najafzadeh, M. ; Pawar, A. ; Déruaz-Luyet, A....
Value in Health. 22 (2019) - p. S161 , 2019

Link: https://doi.org/10.1016/..

12

DM3 QUANTIFYING THE OPPORTUNITY TO REDUCE TOTAL COST OF CAR..:

Schneeweiss, S. ; Eapen, S. ; Jan, S.
Value in Health. 22 (2019) - p. S39 , 2019

Link: https://doi.org/10.1016/..

13

P286Safety and effectiveness of dabigatran relative to warf..:

Gopalakrishnan, C ; Huybrechts, K F ; Ortiz, A S...
European Heart Journal. 39 (2018) suppl_1 - p. , 2018

Link: https://doi.org/10.1093/..

14

CP2 - USING REAL WORLD DATA TO EXTRAPOLATE EVIDENCE FROM RA..:

Wang, S.V. ; Schneeweiss, S. ; Gagne, J.J....
Value in Health. 21 (2018) - p. S5 , 2018

Link: https://doi.org/10.1016/..

15

FRAILTY AND COMPARATIVE EFFECTIVENESS AND SAFETY OF DABIGAT..:

Kim, D H ; Glynn, R J ; Avorn, J..
Innovation in Aging. 2 (2018) suppl_1 - p. 853-853 , 2018

Link: https://doi.org/10.1093/..